Recent briefings covering the 30-day period through 2026-07-03 recorded no material discrete corporate events, regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated 2026-06-09, 2026-06-17, 2026-06-25, and 2026-07-03 each noted the absence of new filings beyond routine reporting cycles, with AbbVie's trailing twelve-month revenue through 31 March 2026 serving as the primary data anchor across all reviewed periods [Brief - 2026-07-03] [Brief - 2026-06-25] [Brief - 2026-06-17].
AbbVie's trailing twelve-month revenue through 31 March 2026 stood at $62.82 billion, representing year-over-year growth of 12.43%. Net income for the same period was $3.64 billion, with a net margin of 5.79% and a gross margin of 67.37%. Operating margin was recorded at 24.41%. The company carried $9.39 billion in cash against total debt of $64.50 billion. Earnings per share declined 45.83% year-over-year, and the price-to-earnings ratio was 122.21 [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership data reflect divergent positioning changes in the most recent reporting period. Bridgewater added 114% to its ABBV position, and Millennium added 61% to its holdings. Conversely, AQR Capital reduced its position by 23%, and Citadel reduced its position by 11% [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Citadel - Q2 2026]. No insider transactions were available in the provided data for this reporting period.
The prevailing macro environment as of the report date shows the 10-year US Treasury yield at 4.54% and the 2-year yield at 4.16%, producing a normal yield curve spread of 38 basis points [FRED DGS10] [FRED DGS2]. This report was generated in response to material institutional position changes identified across multiple large funds in the most recent 13F filings.